Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period

Neonatology

Volumn 98, Issue 2, 2010, Pages 191-199

  Lee, Byong Sop ^a   Byun, Shin Yun ^a   Chung, Mi Lim ^a   Chang, Ji Young ^a   Kim, Hee Young ^a   Kim, Ellen Ai Rhan ^a   Kim, Ki Soo ^a   Pi, Soo Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute renal failure; Creatinine; Cystatin C; Furosemide; Indomethacin; Preterm infants

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPICILLIN; BETAMETHASONE; CREATININE; CYSTATIN C; FUROSEMIDE; GENTAMICIN; INDOMETACIN; PLACEBO; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; KIDNEY FUNCTION; LOW BIRTH WEIGHT; LUNG DYSPLASIA; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MYCOSIS; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN PERIOD; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROLENTAL FIBROPLASIA; SEPSIS; SEPTICEMIA; SODIUM EXCRETION; VERY LOW BIRTH WEIGHT;

CREATININE; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DUCTUS ARTERIOSUS, PATENT; FEMALE; FUROSEMIDE; GESTATIONAL AGE; GLOMERULAR FILTRATION RATE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; KIDNEY; KIDNEY FAILURE, ACUTE; MALE;

EID: 77949448476     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000289206     Document Type: Article

References (33)

1. Itabashi K, Ohno T, Nishida H: Indometha-cin responsiveness of patent ductus arterio-sus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr 2003; 143:203-207.
2. Van Bel F, Guit GL, Schipper J, van de Bor M, Baa n J: Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991; 118:621-626.
3. Friedman Z, Demers L, Marks K, Uhrmann S, Maisels M: Urinary excretion of prosta-glandin following the administration of fu-rosemide and indomethacin to sick low-birth-weight infants. J Pediatr 1978; 93: 512-515. (Pubitemid 8384117)
4. Green TP, Thompson TR, Johnson DE, Lock JE: Furosemide promotes patent ductus a r te-riosus in premature infants with the respiratory distress syndrome. N Engl J Med 1983; 308:743-748.
5. Yeh TF, Wilks A, Singh J, Betkerur M, Lilien L, Pildes RS: Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arterio-sus. J Pediatr 1982; 101:433-437. (Pubitemid 12061470)
6. Vargas-Origel A, Cruz-Anguiano V, Lopez-Montano E: Indomethacin and furosemide in closure of ductus arteriosus (in Spanish). Bol Med Hosp Infant Mex 1986; 43:482-488.
7. Romagnoli C, Zecca E, Papacci P, De Carolis MP, Giannini R, Gallini F, Tortorolo G: Fu-rosemide does not prevent indomethacin-induced renal side effects in preterm infants. Clin Pharmacol Ther 1997; 62 : 181-186.
8. Clyman RI, Chorne N: Patent duct us a r terio-sus: evidence for and against treatment. J Pe-diatr 20 07; 150: 216-219.
9. Gien J: Controversies in the management of patent ductus arteriosus. Neoreviews 2008; 9:e477-482.
10. Fowlie PW, Davis PG: Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002:CD000174.
11. Narayanan M, Cooper B, Weiss H, Clyman RI: Prophylactic indomethacin: factors determining permanent ductus arteriousus closure. J Pediatr 2000; 136: 330-337.
12. Reller M, Rice M, McDonald R: Review of studies evaluating ductal patency in the premature infant. J Pediatr 1993; 122:S59-S62.
13. Clyman RI: Patent ductus arteriosus in the premature infant; in Taeusch HW, Ballard RA, Cleason CA (eds): Avery's Diseases of the Newborn. Philadelphia, Elsevier Saun-ders, 2005, pp 1-816.
14. Young TE, Mangum B: NeoFax: A Manual of Drugs Used in Neonatal Care, ed 20. Mont-vale/NJ, Thomson Healthcare, 2007.
15. Johnson GL, Breart GL, Gewitz MH, Brenner JI, Lang P, Dooley KJ, Ellison RC: Echocar-diographic characteristics of premature infants with patient ductus arteriosus. Pediatrics 1983; 72:864-871.
16. Haycock G, Schwartz G, Wisotsky D: Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 62-66.
17. Choker G, Gouyon JB: Diagnosis of acute renal failure in very preterm infants. Biol Neo-nate 2004; 86:212-216.
18. Sonntag J, Prankel B, Waltz S: Serum creati-nine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1,500 g. Eur J Pediatr 1996; 155: 815-819.
19. Jobe A, Bancalari E: Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163:1723-1729.
20. Bell M, Ternberg J, Feigin R, Keating J, Marshall R, Barton L, Brotherton T: Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978; 187:1-7.
21. Papile L, Burstein J, Burstein R, Koffler H: Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 g. J Pediatr 1978; 92: 529-534.
22. Shimada S, Kasai T, Konishi M, Fujiwara T: Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr 1994; 125:270-277.
23. Harmoinen A, Ylinen E, Ala-Houhala M, Ja-nas M, Kaila M, Kouri T: Reference intervals for cystatin C in pre-and full-term infants and children. Pediatr Nephrol 2000; 15:105-108.
24. Brion LP, Campbell DE: Furosemide for symptomatic patent ductus arteriosus in in-domethacin-treated infants. Cochrane Database Syst Rev 2000:CD001148.
25. Andriessen P, Struis N, Niemarkt H, Oetomo S , Tanke R , Overmeire B: Furosemide i n pre-term infants treated with indomethacin for patent ductus arteriosus. Acta Paediatr 2009; 98: 797-803
26. Eades S, Christensen M: The clinical pharmacology of loop diuretics in the pediatric patient. Pediatr Nephrol 1998; 12:603-616.
27. Mirochnick M, Miceli J, Kramer P, Chapron D, Raye J: Furosemide pharmacokinetics in very low birth weight infants. J Pediatr 1988; 112: 653-657.
28. Montini G, Cosmo L, Amici G, Mussap M, Zacchello G: Plasma cystatin C values and inulin clearances in premature neonates. Pe-diatr Nephrol 2001; 16 : 463-465.
29. Finney H, Newman DJ, Thakkar H, Fell JM, Price CP: Reference ranges for plasma cys-tatin C and creatinine measurements in premature infants, neonates, and older children. Arch Dis Child 2000; 82: 71-75.
30. Armangil D, Yurdakok M, Canpolat FE, Korkmaz A, Yigit S, Tekinalp G: Determination of reference values for plasma cystatin C and comparison with creatinine in premature infants. Pediatr Nephrol 2008; 23: 2081-2083.
31. Takuwa S, Ito Y, Ushijima K, Uchida K: Serum cystatin C values in children by age and their fluctuation during dehydration. Pedi-atr Int 2002; 44: 28-31.
32. Gal P, Ransom JL, Schall S, Weaver RL, Bird A, Brown Y: Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response. J Perinatol 1990; 10:20-26.
33. Chiruvolu A, Jaleel MA: Therapeutic management of patent ductus arteriosus. Early Hum Dev 2009; 85:151-155.